Autor: |
Diaz, Maria, Singh, Priya, Kotchetkov, Ivan S., Skakodub, Anna, Meng, Alicia, Tamer, Christel, Young, Robert J., Reiner, Anne S., Panageas, Katherine S., Ramanathan, Lakshmi V., Pentsova, Elena |
Zdroj: |
Journal of Neuro-Oncology; Mar2022, Vol. 157 Issue 1, p81-90, 10p |
Abstrakt: |
Purpose: Circulating tumor cells in cerebrospinal fluid are a quantitative diagnostic tool for leptomeningeal metastases from solid tumors, but their prognostic significance is unclear. Our objective was to evaluate CSF-CTC quantification in predicting outcomes in LM. Methods: This is a single institution retrospective study of patients with solid tumors who underwent CSF-CTC quantification using the CellSearch® platform between 04/2016 and 06/2019. Information on neuroaxis imaging, CSF results, and survival was collected. LM was diagnosed by MRI and/or CSF cytology. Survival analyses were performed using multivariable Cox proportional hazards modeling, and CSF-CTC splits associated with survival were identified through recursive partitioning analysis. Results: Out of 290 patients with CNS metastases, we identified a cohort of 101 patients with newly diagnosed LM. In this group, CSF-CTC count (median 200 CTCs/3 ml) predicted survival continuously (HR = 1.005, 95% CI: 1.002–1.009, p = 0.0027), and the risk of mortality doubled (HR = 2.84, 95% CI: 1.45–5.56, p = 0.0023) at the optimal cutoff of ≥ 61 CSF-CTCs/3 ml. Neuroimaging findings of LM (assessed by 3 independent neuroradiologists) were associated with a higher CSF-CTC count (median CSF-CTCs range 1.5–4 for patients without radiographic LM vs 200 for patients with radiographic LM, p < 0.001), but did not predict survival. Conclusion: Our data shows that CSF-CTCs quantification predicts survival in newly diagnosed LM, and outperforms neuroimaging. CSF-CTC analysis can be used as a prognostic tool in patients with LM and provides quantitative assessment of disease burden in the CNS compartment. [ABSTRACT FROM AUTHOR] |
Databáze: |
Complementary Index |
Externí odkaz: |
|